A Cell Press partner journal
See the unseen. Change the unchanged.
The Innovation ¡ª published by Cell Press in partnership with members of the Youth
Innovation Promotion Association (YIPA),a part of the Chinese Academy of
Sciences¡ªis a new broad-scope, open access journal publishing basic and applied
research that has impact for the benefit of society.
On the cover: Medicine is the practice of the diagnosis, treatment, and prevention of disease. With the advances in medical science, human beings are getting both longer life spans and higher quality of life. From herbs to molecular signatures, humankind is experiencing a transition from traditional medicine to personalized medicine: the right treatment to the right patient at the right time. However, it is not so easy to achieve this goal because the etiology of most diseases and disorders is still unclear. From description to association, numerous researchers are working together to decipher the mechanisms behind disease. To address such challenges, more and more global collaborations are badly needed to include experts from all disciplines: not just doctors, scientists and administration staff, but also engineers, technicians and marketing managers. Not limited to a fish-eye view, we humans should widen our vision and get more deep insights beyond the human community. That is the right way to assure sustainable healthcare for humanity.
  Related comments
Add comment (English only)
Name*:  
E-mail:  
Telephone:  
Code:    
Comments*:
Position: Home > issue > May 10, 2022 Volume 3, Issue 3
Paclitaxel and Cisplatin with or without Cetuximab in metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-label Phase II trial
Category:   Article   Download:  PDF  Figure  Endnote
Author: Zhihao Lu, Yanqiao Zhang, Qingxia Fan, Yueyin Pan, Da Jiang, Ping Lu, Jingdong Zhang, Xianglin Yuan, Jifeng Feng, Shujun Yang, Wenbin Yue, Lin Zhao, Yunhua Xu, Jinhua Luo, Lin Shen

62.jpg

Graphical abstract


Lack of effective targeted therapy in metastatic esophageal squamous cell carcinoma (ESCC) underscores the urgent need for identifying new treatment approaches for this challenging disease. We sought to assess the addition of cetuximab to paclitaxel-cisplatin chemotherapy for first-line treatment in patients with metastatic ESCC. In this randomized, multicenter, open-label, phase 2 clinical trial, patients were randomized to receive TP [paclitaxel (175 mg/m2 i.v. on day 1 of every 3-week cycle) and cisplatin (75 mg/m2 i.v. on day 1 of every 3-week cycle).





Host
ISSN 2666-6758
Publishing partner
Journal links
 
Academic co-partner
SHANGHAI INSTITUTE OF APPLIED PHYSICS, CAS
INSTITUTE OF MICROBIOLOGY, CAS
XI'AN INSTITUTE OF OPTICS AND PRECISION MECHANICS, CAS
 
Collections

Air Pollution
Astronomy
Cancer
Chemistry & Materials
COVID-19
Environment Changes
Geoscience
Life Science & Medicine
Physics
ScienceX / Interdiscipline

 
Stay connected
  the.innovation.journal
  the.innovation.journal
  The Innovation
  TheInnovation´´ÐÂ
  TheInnovation´´ÐÂ
  The_Innovation
  office@the-innovation.org

Official£º@The_InnovationJ
Astronomy£º@TheInnovationA3
Chemistry£º@InnovationChem
Geoscience£º@TheInnovationG2
Informatics£º@Innovation_inf
Life Science£º@InnovationLS
Management£º@TheInnovationM1
Materials£º@TheInnovationM2
Medicine£º@Theinnovation_m
Physics£º@TheInnovationP1
ScienceX£º@TheInnovSciX

  Copyright © 2019-2022 Youth Innovation All Rights Reserved